Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA warns J&J, CVS, Walgreen over gum health claims
The mouth rinse products include J&J’s Listerine Total Care Anticavity Mouthwash, CVS Complete Care Anticavity Mouthwash and Walgreen Mouth Rinse Full Action. The claims suggest that the products
The mouth rinse products include J&J’s Listerine Total Care Anticavity Mouthwash, CVS Complete Care Anticavity Mouthwash and Walgreen Mouth Rinse Full Action. The claims suggest that the products
Under the contract, HKPI-JV is expected to support the bio pharmaceutical companies to commercialise therapies in Egypt by recruiting, training and placing pharmaceutical sales representatives; forming and managing
The latest agreement follows on the agreement entered in February 2010, in which Starpharma stated that its dendrimer drug delivery technology will be applied to enhance compounds in
Microplasmin, ThromboGenics’ lead drug candidate, is a truncated form of the natural human protein plasmin. ThromboGenics has recently concluded two Phase III trials of Microplasmin, assessing the patients
DX-88 has received approval from the US Food and Drug Administration (FDA) and is marketed as Kalbitor (ecallantide) for the treatment of acute attacks of HAE in patients
Duke joins Johns Hopkins Hospital which is already conducting the Phase I trial of NPC-1C. In addition to Johns Hopkins, North Shore – LIJ has also enrolled patients
As per the terms of the agreement, Eisai is expected to grant Brain Factory the exclusive rights to develop, commercialise, and sublicense ravuconazole prodrug in Japan as an
Rooney has experience in working at management and director levels in the packaging industry within the pharmaceutical and healthcare markets, which will support the Clondalkin’s strategic growth plans
Astellas is seeking an approval for the indication of the prevention of venous thromboembolism (VTE) in patients at risk, such as those undertaking orthopedic surgical procedures in the
UMN-0501 is a cell culture based H5N1 avian influenza vaccine, currently under preparation for Phase III clinical trial in Japan. UMN-0502 is a cell culture based seasonal influenza